Business
Arcadia Biosciences, Inc.: Overview Arcadia has leveraged its history as a leader in science-based approaches to develop high value products and drive innovation in the consumer goods industry.
Revenue decreased 3.7% to $4.9M, while Net income increased 66.8% to ($2.3M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $4.9MWatch
- Profitability — Net income ($2.3M)Watch
- Cash generation — Free cash flow ($4.7M)Note
- Accounting — Formula distress score · manipulation screen not computed · earnings quality greyWatch
- Insiders — 0 buys; 0 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Where the revenue comes from
Fiscal 2025, as Arcadia Biosciences, Inc. reports it. History and quarterly detail are in the app.
- Product$4.9M
Leadership changes
From Arcadia Biosciences, Inc.'s own filings, the day they're filed.
- Albert D. Bolles · director · departureeff. 2026-02-04
- Mark Kawakami · chief financial officer · departureeff. 2025-09-12
- Thomas J. Schaefer · Chief Executive Officer · departureeff. 2025-08-28
Latest filings
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-08-13
- 8-K · Company announcement2026-08-10
- DEF 14A · Annual proxy (pay & governance)2026-08-10
- 8-K · Company announcement2026-07-02
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Arcadia Biosciences, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.